Fig. 6: Subject disposition flow chart in the phase 1 multiple ascending dose (MAD) study. | Nature Communications

Fig. 6: Subject disposition flow chart in the phase 1 multiple ascending dose (MAD) study.

From: Bispecific GLP-1/GLP-2 agonism in advanced type 2 diabetes: preclinical characterization and a randomized, double-blind, placebo-controlled phase I trial

Fig. 6: Subject disposition flow chart in the phase 1 multiple ascending dose (MAD) study.The alternative text for this image may have been generated using AI.

A total of 67 individuals were screened, with 31 meeting the inclusion and exclusion criteria. Of these, 24 participants were enrolled (eight per cohort; randomized 6:2 to PG-102 or placebo) and received the investigational product (IP; PG-102 or placebo). Reasons for exclusion included ineligibility (n = 36), exceeding the subject limit (n = 6), and consent withdrawal prior to enrollment (n = 1). One participant in the 15 mg cohort discontinued after the fourth dose due to an adverse event assessed as unrelated to the IP. The participant completed follow-up safety evaluations and was included in the safety analysis set but excluded from efficacy and pharmacokinetic analyses. †Enrolled = randomized. Source data are provided as a Source data file.

Back to article page